Adult Relapsed Refractory B-cell Acute Lymphoblastic Leukemia: 2021 Updates

Background information regarding the manifestation and prognosis of relapsed/refractory B-cell acute lymphoblastic leukemia.

The treatment approaches available for patients with B-cell acute lymphoblastic leukemia, and reactions to the availability of novel CAR T therapies for relapsed/refractory disease.

Implications of the ZUMA-3 clinical trial of anti-CD19 CAR T-cell therapy for adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Recommendations for sequencing CAR T-cell therapies and other key therapies in patients with B-cell acute lymphoblastic leukemia.

An overview of adverse events commonly associated with CAR T-cell therapies in relapsed/refractory B-cell acute lymphoblastic leukemia.

Emerging therapies in the clinical pipeline for relapsed/refractory B-cell acute lymphoblastic leukemia, as presented at ASH 2021.

When to test for measurable residual disease in B-cell acute lymphoblastic leukemia, and what to keep in mind when selecting a testing method to help assess MRD.

The significance of having novel therapies and molecular tests available to help guide treatment decisions for patients with B-cell acute lymphoblastic leukemia, and recommendations on how to increase the uptake of MRD testing into routine clinical practice.

Discussion on the role of transplantation in the treatment of patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Expectations regarding where novel therapies such as CAR T-cell therapies will fit into B-cell acute lymphoblastic leukemia treatment algorithms as data from clinical trials continue to evolve.

Closing thoughts on advances and future perspectives in the treatment of patients with relapsed/refractory B-cell acute lymphoblastic leukemia.